FDA Approves Genentech’s Lucentis for Additional Indication in DME

Washington Drug Letter
A A
The FDA has approved Genentech’s Lucentis for an additional indication in diabetic macular edema (DME), making it the first and only agency-approved treatment for the condition.

To View This Article:

Login

Buy This Article Now

Add this article to your cart for $25.00